Skip to main content
Top
Published in: Cancer Cell International 1/2020

01-12-2020 | Ovarian Cancer | Primary research

Knockdown of ALPK2 inhibits the development and progression of Ovarian Cancer

Authors: Xiaogang Zhu, Siqi Yan, Songshu Xiao, Min Xue

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Alpha protein kinase 2 (ALPK2) was known to play a vital role in cancer by regulating cell cycle and DNA repair. Ovarian cancer (OC) is one of the most lethal malignancies in the female reproductive system. The emphasis of this study is to explore the role of ALPK2 in OC.

Methods

Firstly, tumor and normal tissues were collected for detecting expression of ALPK2 in OC. Lentivirus-mediated shRNA knockdown of ALPK2 was used to construct OC cell model, which was verified by qRT-PCR and Western blot. The cell proliferation was detected by MTT, cell cycle and apoptosis were measured through flow cytometry. Wound-healing assay was conducted to detect the migration of OC cells.

Results

It was proved that the expression of ALPK2 in OC tissues was significantly higher than that in normal ovarian tissues. Moreover, knockdown of ALPK2 could inhibit proliferation, migration and promote apoptosis, arrested cell cycle of OC cells. It was also found that ALPK2 knockdown inhibited tumor growth in xenograft mice in vivo. Furthermore, ALPK2 was involved in OC cells via regulating EMT-related proteins (N-cadherin, Vimentin and Snail), inhibiting apoptosis-related proteins (Bcl-2, Bcl-w, HSP27, HSP60, IGF-I, IGF-1sR, Survivin and XIAP), as well as the regulation of downstream pathways (Akt, p-Akt, Cyclin D1, CDK6 and PIK3CA).

Conclusions

In conclusion, ALPK2 might serve as an optional target for prognosis and therapeutic of OC patients.
Literature
1.
go back to reference Saracci R, Wild CP. Fifty years of the International agency for research on cancer (1965 to 2015). Int J Cancer. 2016;138(6):1309–11.PubMedCrossRef Saracci R, Wild CP. Fifty years of the International agency for research on cancer (1965 to 2015). Int J Cancer. 2016;138(6):1309–11.PubMedCrossRef
2.
go back to reference Prat J, D’Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol. 2018;80:11–27.PubMedCrossRef Prat J, D’Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol. 2018;80:11–27.PubMedCrossRef
4.
go back to reference Heintz AP, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):161–92.CrossRef Heintz AP, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):161–92.CrossRef
5.
go back to reference Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2014;342(2):257–63.PubMedCrossRef Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2014;342(2):257–63.PubMedCrossRef
6.
go back to reference Oikonomopoulou K, et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer. 2008;99(7):1103–13.PubMedPubMedCentralCrossRef Oikonomopoulou K, et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer. 2008;99(7):1103–13.PubMedPubMedCentralCrossRef
7.
go back to reference Zhang HJ, et al. Abnormal gene expression profile reveals the common key signatures associated with clear cell renal cell carcinoma: a meta-analysis. Genet Mol Res. 2015;14(1):2216–24.PubMedCrossRef Zhang HJ, et al. Abnormal gene expression profile reveals the common key signatures associated with clear cell renal cell carcinoma: a meta-analysis. Genet Mol Res. 2015;14(1):2216–24.PubMedCrossRef
8.
go back to reference Middelbeek J, et al. The alpha-kinase family: an exceptional branch on the protein kinase tree. Cell Mol Life Sci. 2010;67(6):875–90.PubMedCrossRef Middelbeek J, et al. The alpha-kinase family: an exceptional branch on the protein kinase tree. Cell Mol Life Sci. 2010;67(6):875–90.PubMedCrossRef
9.
go back to reference Ryazanov AG, Pavur KS, Dorovkov MV. Alpha-kinases: a new class of protein kinases with a novel catalytic domain. Curr Biol. 1999;9(2):R43–5.PubMedCrossRef Ryazanov AG, Pavur KS, Dorovkov MV. Alpha-kinases: a new class of protein kinases with a novel catalytic domain. Curr Biol. 1999;9(2):R43–5.PubMedCrossRef
10.
go back to reference Yoshida Y, et al. ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model. Anticancer Res. 2012;32(6):2301–8.PubMed Yoshida Y, et al. ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model. Anticancer Res. 2012;32(6):2301–8.PubMed
12.
go back to reference Sangha N, et al. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia. 2008;10(12):1362–72.PubMedPubMedCentralCrossRef Sangha N, et al. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia. 2008;10(12):1362–72.PubMedPubMedCentralCrossRef
14.
go back to reference Patch AM, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–94.PubMedCrossRef Patch AM, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–94.PubMedCrossRef
15.
go back to reference Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.CrossRef Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.CrossRef
16.
go back to reference Jurmeister P, et al. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma—a combined IHC score for melanoma risk stratification. J Dtsch Dermatol Ges. 2019;17(8):800–8.PubMed Jurmeister P, et al. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma—a combined IHC score for melanoma risk stratification. J Dtsch Dermatol Ges. 2019;17(8):800–8.PubMed
17.
19.
go back to reference Xia D, et al. Over-expression of CHAF1A in epithelial ovarian cancer can promote cell proliferation and inhibit cell apoptosis. Biochem Biophys Res Commun. 2017;486(1):191–7.PubMedCrossRef Xia D, et al. Over-expression of CHAF1A in epithelial ovarian cancer can promote cell proliferation and inhibit cell apoptosis. Biochem Biophys Res Commun. 2017;486(1):191–7.PubMedCrossRef
20.
21.
go back to reference Nishi K, et al. An Alpha-kinase 2 gene variant disrupts filamentous actin localization in the surface cells of colorectal cancer spheroids. Anticancer Res. 2017;37(7):3855–62.PubMed Nishi K, et al. An Alpha-kinase 2 gene variant disrupts filamentous actin localization in the surface cells of colorectal cancer spheroids. Anticancer Res. 2017;37(7):3855–62.PubMed
23.
go back to reference Salim H, et al. miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression. Genes Chromosomes Cancer. 2013;52(10):895–911.PubMedCrossRef Salim H, et al. miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression. Genes Chromosomes Cancer. 2013;52(10):895–911.PubMedCrossRef
24.
go back to reference Junnila S, et al. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer. 2010;10:73.PubMedPubMedCentralCrossRef Junnila S, et al. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer. 2010;10:73.PubMedPubMedCentralCrossRef
25.
go back to reference Suster NK, Smrkolj S, Virant-Klun I. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers. J Ovarian Res. 2017;10(1):11.CrossRef Suster NK, Smrkolj S, Virant-Klun I. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers. J Ovarian Res. 2017;10(1):11.CrossRef
29.
go back to reference Liu X, et al. The effect of thymoquinone on apoptosis of SK-OV-3 ovarian cancer cell by regulation of Bcl-2 and bax. Int J Gynecol Cancer. 2017;27(8):1596–601.PubMedCrossRef Liu X, et al. The effect of thymoquinone on apoptosis of SK-OV-3 ovarian cancer cell by regulation of Bcl-2 and bax. Int J Gynecol Cancer. 2017;27(8):1596–601.PubMedCrossRef
30.
go back to reference Xu L, et al. Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2 + signaling in SKOV3 cells. Oncol Rep. 2018;39(3):985–92.PubMed Xu L, et al. Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2 + signaling in SKOV3 cells. Oncol Rep. 2018;39(3):985–92.PubMed
31.
go back to reference Zhao M, et al. Heat shock protein 27: a potential biomarker of peritoneal metastasis in epithelial ovarian cancer? Tumour Biol. 2014;35(2):1051–6.PubMedCrossRef Zhao M, et al. Heat shock protein 27: a potential biomarker of peritoneal metastasis in epithelial ovarian cancer? Tumour Biol. 2014;35(2):1051–6.PubMedCrossRef
32.
33.
go back to reference Liefers-Visser JAL, et al. IGF system targeted therapy: therapeutic opportunities for ovarian cancer. Cancer Treat Rev. 2017;60:90–9.PubMedCrossRef Liefers-Visser JAL, et al. IGF system targeted therapy: therapeutic opportunities for ovarian cancer. Cancer Treat Rev. 2017;60:90–9.PubMedCrossRef
36.
go back to reference Abe A, et al. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Hum Pathol. 2013;44(2):199–207.PubMedCrossRef Abe A, et al. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Hum Pathol. 2013;44(2):199–207.PubMedCrossRef
37.
go back to reference Mabuchi S, et al. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137(1):173–9.PubMedCrossRef Mabuchi S, et al. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137(1):173–9.PubMedCrossRef
38.
39.
go back to reference Barbieri F, et al. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res. 1999;5(7):1837–42.PubMed Barbieri F, et al. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res. 1999;5(7):1837–42.PubMed
40.
go back to reference Zhong Q, et al. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib. Gynecol Oncol. 2019;152(1):157–65.PubMedCrossRef Zhong Q, et al. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib. Gynecol Oncol. 2019;152(1):157–65.PubMedCrossRef
41.
Metadata
Title
Knockdown of ALPK2 inhibits the development and progression of Ovarian Cancer
Authors
Xiaogang Zhu
Siqi Yan
Songshu Xiao
Min Xue
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01347-z

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine